BMP2 gene therapy on the repair of bone defects of aged rats.
Age-related decline in the number of mesenchymal stem cells (MSCs) and their reduced capability to differentiate osteogenically, along with diminished availability of growth factors, may be major factors accounting for reduced bone formation in the aging mammalian body. In the first part of the study, we compared the number of MSCs in bone marrow (BM) and the content of bone morphogenetic protein 2 (BMP2) in cortical bone tissue in juvenile, adult, and aged (1, 9, and 24 months, respectively) male rats. To assay the influence of aging on osteogenic differentiation ability, MSCs from the three age groups were transduced with the BMP2 gene. Following gene transduction, the production of BMP2 in culture media, expression of osteogenic proteins (e.g., alkaline phosphatase, type Ialpha1 collagen, osteopontin, and bone sialoprotein), as well as ectopic bone formation in athymic mice were compared. Results showed that the number of MSCs in BM as well as the content of BMP2 in cortical bone tissue decreased with age, but no significant differences between the three age groups were found with regard to production of BMP2 or capability of BMP2 gene-modified MSCs to differentiate osteogenically. The second part of the study applied BMP2 gene-modified autologous MSCs/beta-tricalcium phosphate for repair of bone defects in aged rats with positive results. Our data indicate that the osteogenic potential of MSCs of aged rats can be restored following BMP2 gene transduction and that this technique may be a useful approach in the future planning of gene therapy for age-related osteoporotic fractures.
Yue
B
B
Department of Orthopedics, Ninth People's Hospital, Shanghai Second Medical University, Shanghai, People's Republic of China.
Lu
B
B
Dai
K R
KR
Zhang
X L
XL
Yu
C F
CF
Lou
J R
JR
Tang
T T
TT
D000256:Adenoviridae / Q000235:genetics; D000375:Aging / Q000502:physiology*; D000469:Alkaline Phosphatase / Q000378:metabolism; D000818:Animals; D001847:Bone Diseases / Q000628:therapy*; D001853:Bone Marrow / Q000378:metabolism*; D055396:Bone Morphogenetic Protein 2; D019485:Bone Morphogenetic Proteins / Q000235:genetics* / Q000378:metabolism; D001861:Bone Regeneration / Q000502:physiology*; D017077:Culture Media, Conditioned / Q000737:chemistry / Q000378:metabolism; D005269:Femur / Q000187:drug effects / Q000473:pathology / Q000601:surgery; D015316:Genetic Therapy; D008297:Male; D045164:Mesenchymal Stem Cell Transplantation; D059630:Mesenchymal Stem Cells / Q000378:metabolism*; D051379:Mice; D008819:Mice, Nude; D010012:Osteogenesis / Q000502:physiology; D051381:Rats; D017208:Rats, Wistar; D013234:Stem Cells; D014161:Transduction, Genetic; D016212:Transforming Growth Factor beta / Q000235:genetics* / Q000378:metabolism
C525719:Bmp2 protein, mouse; C525720:Bmp2 protein, rat; D055396:Bone Morphogenetic Protein 2; D019485:Bone Morphogenetic Proteins; D017077:Culture Media, Conditioned; D016212:Transforming Growth Factor beta; D000469:Alkaline Phosphatase